Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ICP-248 for efficacy and safety in relapsed or refractory mantle cell lymphoma, currently recruiting (APEX-06).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• ICP-248

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING